News
IDRSF
5.06
NaN%
--
Idorsia Maintained at Buy as New Phase 3 Data Strengthen Aprocitentan Profile; 12‑Month Price Target Reaffirmed at CHF5
TipRanks · 06/02 12:36
Buy Rating Reaffirmed on Daridorexant Growth Prospects; 12‑Month Price Target Maintained at $5
TipRanks · 05/26 10:35
Kepler Capital Remains a Buy on Idorsia Ltd (IDIA)
TipRanks · 04/30 01:47
Idorsia Q1 QUVIVIQ Revenue Improves; Reaffirms 2026 Sales Guidance
NASDAQ · 04/28 10:27
Idorsia Ltd (IDIA) Receives a Rating Update from a Top Analyst
TipRanks · 04/01 01:46
Idorsia: Positive Pediatric Daridorexant Data and Neurodevelopmental Expansion Drive Buy Rating and CHF5 Target
TipRanks · 03/31 10:36
Idorsia's Daridorexant Shows Positive Phase 2 Results In Paediatric Insomnia; Stock Up
NASDAQ · 03/30 11:03
Idorsia: Leadership Reset and Pipeline Expansion Underpin Buy Rating and CHF5 Price Target
TipRanks · 03/18 10:15
Idorsia: Expanding QUVIVIQ Footprint and Aprocitentan Upside Support Buy Rating Despite Lowered Target
TipRanks · 03/13 10:35
Idorsia price target lowered to CHF 5 from CHF 6 at H.C. Wainwright
TipRanks · 03/13 10:10
Kepler Capital Sticks to Their Buy Rating for Idorsia Ltd (IDIA)
TipRanks · 03/12 02:05
Idorsia Ltd (IDIA) Receives a Buy from Kepler Capital
TipRanks · 02/28 01:50
Idorsia Earnings Call Signals Turnaround, Risks Linger
TipRanks · 02/27 00:03
Idorsia reports FY results
Seeking Alpha · 02/26 16:54
Idorsia: FDA-Aligned Phase 3 Pathway and Broad Fabry Disease Positioning Support Buy Rating and CHF6 Target
TipRanks · 02/09 12:06
Idorsia Ltd (IDIA) Receives a Buy from Kepler Capital
TipRanks · 01/30 12:06
Idorsia: Latin America QUVIVIQ Deal and Pipeline Optionality De‑Risk Path to Profitability, Supporting Reiterated Buy Rating
TipRanks · 01/29 11:35
Idorsia: Differentiated Insomnia and Hypertension Assets, Understated Guidance, and Pipeline Upside Support Reiterated Buy Rating
TipRanks · 01/20 11:38
Idorsia Advances Fabry Disease Program With Encouraging Phase 3 Results
NASDAQ · 01/12 07:29
Idorsia: Cardiovascular Franchise Momentum and Underappreciated Pipeline Drive Buy Rating and Valuation Upside
TipRanks · 01/05 11:25
More
Webull provides a variety of real-time IDRSF stock news. You can receive the latest news about Idorsia through multiple platforms. This information may help you make smarter investment decisions.
About IDRSF
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.